← 返回

肿瘤内 CXCL13(+) CD160(+) CD8(+) T 细胞促进三级淋巴结构形成,增强晚期胃癌免疫治疗疗效

英文原题:Intratumoral CXCL13(+) CD160(+) CD8(+) T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer.

查看英文原题

Intratumoral CXCL13(+) CD160(+) CD8(+) T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer.

PubMed 2024/09/06(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TLS 的数量和成熟度,以及 CXCL13 + CD160 + CD8 + T 细胞浸润的程度,可能作为评估免疫治疗在治疗胃恶性肿瘤中有效性的潜在指标。此外,我们的研究表明,维生素 B 6 可以通过减少 HIF-1α的降解来增强 CD160 + CD8 + T 细胞分泌 CXCL13。另外,我们证明补充维生素 B 6 或靶向吡哆醛激酶可以显著提高胃癌免疫治疗的疗效。

研究思路结论见上方概要

IV期胃癌是一种高度异质性和致死性的肿瘤,治疗策略很少。程序性细胞死亡蛋白1抑制剂联合化疗目前是晚期胃癌的标准一线治疗方案。然而,筛选免疫化疗的获益人群并扩大该治疗方案的适应症仍然是一个巨大的挑战。

我们进行了一项病理学评估,以确定基于IV期胃癌患者(n=15)在免疫化疗治疗前后收集的组织样本中三级淋巴结构的重要性。此外,我们使用空间转录分析(n=10)和单细胞转录分析(n=97)来研究三级淋巴结构(TLSs)的关键调控因子。进行了多重免疫荧光和图像分析(n=34),以探讨肿瘤浸润性CXCL13 + CD160 + CD8 + T细胞与TLSs之间的关联。还通过多重免疫荧光和图像分析方法(n=15)评估了CXCL13 + CD160 + CD8 + T细胞与免疫治疗反应性之间的关系。此外,我们通过多种实验技术,包括定量逆转录PCR、western blot和流式细胞术,探索了CXCL13 + CD160 + CD8 + T细胞的内在特征。

我们发现,与无应答者相比,应答者在免疫化疗前的活检组织中表现出更高水平的TLSs和CXCL13 + CD160 + CD8 + T细胞。转换治疗后,应答者在手术切除标本中也具有更高比例的成熟TLSs和更多的CXCL13 + CD160 + CD8 + T细胞。此外,我们发现CD160 + CD8 + T细胞中的维生素B 6可减少MDM2对HIF-1α的泛素化修饰,从而减弱HIF-1α的降解。因此,这导致CXCL13表达的转录上调,促进CXCR5 + B细胞的募集和TLSs的形成。

展开英文摘要原文

Stage IV gastric cancer is a highly heterogeneous and lethal tumor with few therapeutic strategies. The combination of programmed cell death protein 1 inhibitors and chemotherapy is currently the standard frontline treatment regimen for advanced gastric cancer. Nevertheless, it remains a great challenge to screen the beneficiaries of immunochemotherapy and expand indications for this treatment regimen.

We conducted a pathological assessment to ascertain the importance of tertiary lymphoid structures based on the tissue samples collected from patients with stage IV gastric cancer (n=15) both prior to and following immunochemotherapy treatment. Additionally, we used spatial (n=10) and single-cell transcriptional analysis (n=97) to investigate the key regulators of tertiary lymphoid structures (TLSs). Multiplex immunofluorescence and image analysis (n=34) were performed to explore the association between tumor-infiltrating CXCL13 + CD160 + CD8 + T cells and TLSs. The relationship between CXCL13 + CD160 + CD8 + T cells and the responsiveness to immunotherapy was also evaluated by multiplex immunofluorescence and image analysis approaches (n=15). Furthermore, we explored the intrinsic characteristics of CXCL13 + CD160 + CD8 + T cells through various experimental techniques, including quantitative reverse transcription-PCR, western blot, and flow cytometry.

We found that responders exhibited higher levels of TLSs and CXCL13 + CD160 + CD8 + T cells in biopsy tissues prior to immunochemotherapy compared with non-responders. Following conversion therapy, responders also had a higher percentage of mature TLSs and a higher number of CXCL13 + CD160 + CD8 + T cells in surgical resections. Moreover, we discovered that vitamin B 6 in CD160 + CD8 + T cells could reduce the ubiquitination modification of HIF-1α by MDM2, thereby attenuating the degradation of HIF-1α. Consequently, this led to the transcriptional upregulation of CXCL13 expression, facilitating the recruitment of CXCR5 + B cells and the formation of TLSs.

The number and maturity of TLSs, along with the extent of CXCL13 + CD160 + CD8 + T-cell infiltration, might function as potential indicators for assessing the effectiveness of immunotherapy in treating gastric malignancies. Furthermore, our research suggests that vitamin B 6 could enhance the secretion of CXCL13 by CD160 + CD8 + T cells by reducing the degradation of HIF-1α. Additionally, we demonstrate that vitamin B 6 supplementation or targeting pyridoxal kinase could substantially improve the efficacy of immunotherapies for gastric cancer.

论文信息

作者
Wang J、Liang Y、Xue A、Xiao J、Zhao X、Cao S、Li P、Dong J
第一作者单位
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.China
通讯作者单位
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China pwkyangli@njmu.edu.cn.China
期刊
Journal for immunotherapy of cancer2024 Sep 6
原文标识
PubMed 39244216 · DOI 10.1136/jitc-2024-009603